Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Pryde, David C ^a   Jones, Lyn H ^b   Gervais, David P ^b,d   Stead, David R ^b   Blakemore, David C ^a   Selby, Matthew D ^b,e   Brown, Alan D ^a   Coe, Jotham W ^b   Badland, Matthew ^a   Beal, David M ^b,f   Glen, Rebecca ^c   Wharton, Yvonne ^c,g   Miller, Gavin J ^c,h   White, Phil ^b   Zhang, Ningli ^b   Benoit, Michelle ^b   Robertson, Karen ^b   Merson, James R ^b   Davis, Heather L ^b   McCluskie, Michael J ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

^c CXR Biosciences Ltd   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e UCB PHARMA   (Belgium)

^f UNIVERSITY OF KENT   (United Kingdom)

^g C Tech Innovation Ltd   (United Kingdom)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (1 METHYLPYRROLIDIN 2 YL)PYRIDIN 2 YLOXY]ETHANAMINE DIPHTHERIA TOXOID VACCINE; 2 [3 (1 METHYLPYRROLIDIN 2 YL)PYRIDIN 4 YLOXY]ETHANAMINE DIPHTHERIA TOXOID VACCINE; 2 [5 (1 METHYLPYRROLIDIN 2 YL)PYRIDIN 2 YLOXY]ETHANAMINE DIPHTHERIA TOXOID VACCINE; 2 [5 (1 METHYLPYRROLIDIN 2 YL)PYRIDIN 3 YL]PROPANOIC ACID DIPHTHERIA TOXOID VACCINE; 2 [5 (1 METHYLPYRROLIDIN 2 YL)PYRIDIN 3 YLOXY]ETHANAMINE DIPHTHERIA TOXOID VACCINE; 3 (1' METHYL 5,6 DIHYDROSPIRO[CYCLOPENTAL[C]PYRIDINE 7,2' PYRROLIDINE] 4 YL)PROPANOIC ACID SODIUM SALT DIPHTHERIA TOXOID VACCINE; 3 [5 (1 METHYLPIPERIDIN 2 YL)PYRIDIN 3 YL]PROPANOIC ACID SODIUM SALT DIPHTHERIA TOXOID VACCINE; 3 [5 (1 METHYLPYRROLIDIN 2 YL)PYRIDIN 3 YL]PROPANOIC ACID DIPHTHERIA TOXOID VACCINE; 3 [5 (1 METHYLPYRROLIDIN 2 YL)PYRIDIN 3 YL]PROPYL ETHANETHIOATE DIPHTHERIA TOXOID VACCINE; 3 [5 (1 METHYLPYRROLIDIN 2 YL)PYRIDIN 3YL]PROPAN 1 AMINE DIPHTHERIA TOXOID VACCINE; 3' AMINOMETHYLNICOTINE DIPHTHERIA TOXOID VACCINE; 5 AMINOETHOXY NICOTINE DIPHTHERIA TOXOID VACCINE; ALUMINUM HYDROXIDE; ANTIBODY; ANTIBODY CONJUGATE; CPG OLIGODEOXYNUCLEOTIDE; DIPHTHERIA TOXOID; HAPTEN; N (2 AMINOETHYL) 5 (1 METHYLPYRROLIDIN 2 YL)NICOTINAMIDE DIPHTHERIA TOXOID VACCINE; NICOTINE; NICOTINE ANTIBODY; NICOTINE TARTRATE; NICOTINE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY LABELING; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN FUNCTION; ARTICLE; B LYMPHOCYTE; BRAIN; CELL POLARITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; ISOTOPE LABELING; MOUSE; NONHUMAN; PLASMA; RIGIDITY; SMOKING CESSATION; T LYMPHOCYTE; VACCINE FAILURE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS; DIPHTHERIA TOXOID; FEMALE; HAPTENS; HUMANS; IMMUNOCONJUGATES; MICE; MICE, INBRED BALB C; MOLECULAR MIMICRY; NICOTINE; OLIGODEOXYRIBONUCLEOTIDES; PROTEIN ENGINEERING; SMOKING; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES;

EID: 84885036250     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076557     Document Type: Article

References (37)

1. World Health Organization (2011) WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco.
2. Hughes JR, Keely J, Naud S, (2004) Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 99: 29-38. doi:10.1111/j.1360-0443.2004.00540.x. PubMed: 14678060.
3. Nides M, Glover ED, Reus VI, Christen AG, Make BJ, et al. (2008) Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 32: 664-675. PubMed: 18442345.
4. Hatsukami DK, Stead LF, Gupta PC, (2008) Tobacco addiction. Lancet 371: 2027-2038. doi:10.1016/S0140-6736(08)60871-5. PubMed: 18555914.
5. Raupach T, Hoogsteder PH, Onno van Schayck CP, (2012) Nicotine vaccines to assist with smoking cessation: current status of research. Drugs 72: e1-16. doi:10.2165/11633630-000000000-00000. PubMed: 22356293.
6. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, et al. (2008) A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLOS ONE 3: e2547. doi:10.1371/journal.pone.0002547. PubMed: 18575629.
7. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, et al. (2011) Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 89: 392-399. doi:10.1038/clpt.2010.317. PubMed: 21270788.
8. McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, et al. (2013) Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol: 16: 50-56. doi:10.1016/j.intimp.2013.03.021. PubMed: 23562759.
9. Esterlis I, Hannestad JO, Perkins E, Bois F, D'Souza DC, et al. (2013) Effect of a Nicotine Vaccine on Nicotine Binding to beta2*-Nicotinic Acetylcholine Receptors In Vivo in Human Tobacco Smokers. Am J Psychiatry: 170: 399-407. doi:10.1176/appi.ajp.2012.12060793. PubMed: 23429725.
10. Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, et al. (2012) Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 83: 543-550. doi:10.1016/j.bcp.2011.11.004. PubMed: 22100986.
11. Meijler MM, Matsushita M, Altobell LJ III, Wirsching P, Janda KD, (2003) A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc 125: 7164-7165. doi:10.1021/ja034805t. PubMed: 12797775.
12. Moreno AY, Azar MR, Koob GF, Janda KD, (2012) Probing the protective effects of a conformationally constrained nicotine vaccine. Vaccine 30: 6665-6670. doi:10.1016/j.vaccine.2012.08.064. PubMed: 22963803.
13. Keyler DE, Roiko SA, Earley CA, Murtaugh MP, Pentel PR, (2008) Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 8: 1589-1594. doi:10.1016/j.intimp.2008.07.001. PubMed: 18656557.
14. de Villiers SH, Lindblom N, Kalayanov G, Gordon S, Baraznenok I, et al. (2010) Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine 28: 2161-2168. doi:10.1016/j.vaccine.2009.12.051. PubMed: 20060511.
15. Murphy JM, Liao X, Hartwig JF, (2007) Meta halogenation of 1,3-disubstituted arenes via iridium-catalyzed arene borylation. J Am Chem Soc 129: 15434-15435. doi:10.1021/ja076498n. PubMed: 18027947.
16. Février FC, Smith ED, Comins DL, (2005) Regioselective C-2 and C-6 substitution of (S)-nicotine and nicotine derivatives. Org Lett 7: 5457-5460. doi:10.1021/ol052196j. PubMed: 16288530.
17. Choppin S, Gros P, Fort Y, (2000) Unusual C-6 Lithiation of 2-Chloropyridine-Mediated by BuLi-Me(2)N(CH(2))(2)OLi. New Access to 6-Functional-2-chloropyridines and Chloro-bis-heterocycles. Org Lett 2: 803-805.
18. Gros PC, Doudouh A, Woltermann C, (2006) TMSCH2Li-induced regioselective lithiation of (S)-nicotine. Org Biomol Chem 4: 4331-4335. doi:10.1039/b612786j. PubMed: 17102878.
19. Ullrich T, Krich S, Binder D, Mereiter K, Anderson DJ, et al. (2002) Conformationally constrained nicotines: polycyclic, bridged, and spiro-annulated analogues as novel ligands for the nicotinic acetylcholine receptor. J Med Chem 45: 4047-4054. doi:10.1021/jm020916b. PubMed: 12190326.
20. Benowitz NL, Jacob P III, (1984) Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35: 499-504. doi:10.1038/clpt.1984.67. PubMed: 6705448.
21. Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX, (2012) High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 31: 159-164. doi:10.1016/j.vaccine.2012.10.069. PubMed: 23123021.
22. Cerny EH, Lévy R, Mauel J, Mpandi M, Mutter M, et al. (2002) Preclinical development of a vaccine 'against smoking'. Onkologie 25: 406-411. doi:10.1159/000067433. PubMed: 12415193.
23. Langone JJ, Gjika HB, Van Vunakis H, (1973) Nicotine and its metabolites. Radioimmunoassays for nicotine and cotinine. Biochemistry 12: 5025-5030. doi:10.1021/bi00748a032. PubMed: 4761980.
24. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, et al. (2000) A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65: 191-198. doi:10.1016/S0091-3057(99)00206-3. PubMed: 10638653.
25. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR, (2000) Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 22: 809-819. doi:10.1016/S0192-0561(00)00042-4. PubMed: 10963853.
26. Isomura S, Wirsching P, Janda KD, (2001) An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J Org Chem 66: 4115-4121. doi:10.1021/jo001442w. PubMed: 11397142.
27. Moreno AY, Azar MR, Warren NA, Dickerson TJ, Koob GF, et al. (2010) A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm 7: 431-441. doi:10.1021/mp900213u. PubMed: 20104903.
28. Matsukura S, Sakamoto N, Imura H, Matsuyama H, Tamada T, et al. (1975) Radioimmunoassay of nicotine. Biochem Biophys Res Commun 64: 574-580. doi:10.1016/0006-291X(75)90360-5. PubMed: 1170854.
29. Carroll FI, Blough BE, Pidaparthi RR, Abraham P, Gong PK, et al. (2011) Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem 54: 5221-5228. doi:10.1021/jm2004943. PubMed: 21682289.
30. Moreno AY, Mayorov AV, Janda KD, (2011) Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc 133: 6587-6595. doi:10.1021/ja108807j. PubMed: 21473576.
31. Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, et al. (2007) Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther 322: 30-39. doi:10.1124/jpet.106.117150. PubMed: 17452421.
32. Carroll FI, Abraham P, Gong PK, Pidaparthi RR, Blough BE, et al. (2009) The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem 52: 7301-7309. doi:10.1021/jm901134w. PubMed: 19877685.
33. Harris JM, Chess RB, (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221. doi:10.1038/nrd1033. PubMed: 12612647.
34. Jones LH, Altobell LJ III, MacDonald MT, Boyle NA, Wentworth P Jr., et al. (2002) Active immunization with a glycolipid transition state analogue protects against endotoxic shock. Angew Chem Int Ed Engl 41: 4241-4244. doi:10.1002/1521-3773(20021115)41:22. PubMed: 12434351.
35. Storer RI, Aciro C, Jones LH, (2011) Squaramides: physical properties, synthesis and applications. Chem Soc Rev 40: 2330-2346. doi:10.1039/c0cs00200c. PubMed: 21399835.
36. Xu Y, Yamamoto N, Ruiz DI, Kubitz DS, Janda KD, (2005) Squaric monoamide monoester as a new class of reactive immunization hapten for catalytic antibodies. Bioorg Med Chem Lett 15: 4304-4307. doi:10.1016/j.bmcl.2005.06.052. PubMed: 16046128.
37. McCluskie MJ, Thorn J, Mehelic P, Chikh G, Benoit M, et al. (2013) Nic7-001, A novel anti-nicotine vaccine, shows significantly superior function in non-human primates (NHP) compared to a CYT002-NicQb mimetic. 19th Annual Meeting of the Society for Research on Nicotine and Tobacco, Boston, MA, USA. March, 2013.: Abstract PA13-4.